Improved Pharma Announces Pharmaceutical R&D Efforts in 2021
Retrieved on:
Friday, January 14, 2022
Research, AAPS PharmSciTech, PDF, Canadian International Council, Poly, Excipient, DSC, Sumitomo Chemical, Lapatinib, Plasma, Salt (chemistry), Efficiency, Environment, SSCI, Bedaquiline, THF, Particle-size distribution, X-ray crystallography, Dow Chemical Company, Risk, FBZ, XRD, Publication, Adult, AAPS, NMR, Ion, Pharmacy, Solubility, ASD, Section, Tuberculosis, Solvent, RH, Ageing, PEO Soldier, Solution, Computer scientist, NCL, TGA, International Journal of Pharmaceutics, Behavior, IR, Particle size, ADFS, Journal, CSO, Atomic mass, USFDA, Niclosamide, TB, Tablet, Population, PEO, Salt, Consultant, Polymer, ADF, Drug development, Heckel, Patent, Journal of Pharmaceutical Sciences, Ethylene oxide, Pharmaceutical industry, Fine chemical, Sulfur, Animal, Aluminium, Indometacin
WEST LAFAYETTE, Ind., Jan. 14, 2022 /PRNewswire-PRWeb/ -- Developing new tools and advancing pharmaceutical development is a key part of Improved Pharma's mission.
Key Points:
- WEST LAFAYETTE, Ind., Jan. 14, 2022 /PRNewswire-PRWeb/ -- Developing new tools and advancing pharmaceutical development is a key part of Improved Pharma's mission.
- In 2021, the results from several research and development projects were published with our team of consultants and collaborators.
- "This past year has been very exciting for the Improved Pharma team," exclaims Dr. Stephen Byrn, CSO of Improved Pharma.
- Improved Pharma is a research, consulting, and information company dedicated to improving pharmaceutical methods, formulations, and processes.